Disease burden and treatment sequence of polymyositis and dermatomyositis patients in Japan: a real-world evidence study.
Dermatomyositis
Healthcare resource utilization
Polymyositis
Treatment choice
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
08
07
2021
accepted:
22
09
2021
revised:
17
09
2021
pubmed:
23
10
2021
medline:
1
3
2022
entrez:
22
10
2021
Statut:
ppublish
Résumé
Since new consensus on polymyositis (PM) and dermatomyositis (DM) were released in Japan, an updated evidence on treatment landscape and PM/DM burden was essential. This study evaluates treatment burden and overall treatment cost of PM/DM-related inpatient and outpatient visits, treatments, and procedures/patient/year. This retrospective, observational study analyzed insurance claims from Japan Medical Data Center (JMDC) database. Patients with at least one PM/DM diagnosis/one dispensation of treatment between 1 January 2009 and 31 December 2019 were enrolled. Patient characteristics, treatment patterns and sequence, treatment choices, healthcare resource utilization (HCRU), and related costs were assessed. Chi-square test and linear regression model were used to assess impact of patient characteristics on treatment choice. Patients (836/4,961) receiving a relevant treatment were analyzed. Heart disease (35%), interstitial lung disease (27%), and diabetes mellitus (26%) were frequently identified as comorbidities. Concomitant dispensation of immunosuppressants and systemic steroids was largely found in first and second line of treatment (LoT) while systemic steroids remained as single dominant treatment across all LoTs. HCRU was very low for inpatient visits (0.68 [1.43]) or rehabilitation (4.74 [14.57]). The mean (SD) number of inpatient visits decreased from first (1.23 [2.32]) to third year (0.11 [0.54]). Total mean (SD) healthcare cost per patients per year was ¥ 3,815,912 (7,412,241), with overall drug dispensation compounding to 80% of total cost. High concomitant immunosuppressant and systemic steroid prescriptions in first LoT recommend early optimal treatment to manage PM/DM. Although inpatient costs are low, outpatient dispensation costs increase overall economic burden.
Identifiants
pubmed: 34677707
doi: 10.1007/s10067-021-05939-6
pii: 10.1007/s10067-021-05939-6
pmc: PMC8873135
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
741-755Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Findlay AR, Goyal NA, Mozaffar T (2015) An overview of polymyositis and dermatomyositis. Muscle Nerve 51(5):638–656
doi: 10.1002/mus.24566
Lundberg IE, de Visser M, Werth VP (2018) Classification of myositis. Nat Rev Rheumatol 14(5):269–278
doi: 10.1038/nrrheum.2018.41
Dalakas MC (2015) Inflammatory muscle diseases. N Engl J Med 372(18):1734–1747
doi: 10.1056/NEJMra1402225
Marie I, Mouthon L (2011) Therapy of polymyositis and dermatomyositis. Autoimmun Rev 11(1):6–13
doi: 10.1016/j.autrev.2011.06.007
Yang SH, Chang C, Lian ZX (2019) Polymyositis and dermatomyositis - challenges in diagnosis and management. J Transl Autoimmun 2:100018. https://doi.org/10.1016/j.jtauto.2019.100018
doi: 10.1016/j.jtauto.2019.100018
pubmed: 32743506
pmcid: 7388349
Ohta A, Nagai M, Nishina M, Tomimitsu H, Kohsaka H (2014) Prevalence and incidence of polymyositis and dermatomyositis in Japan. Mod Rheumatol 24(3):477–480
doi: 10.3109/14397595.2013.844308
Ohta A, Nagai M, Nishina M, Tomimitsu H, Kohsaka H (2013) Age at onset and gender distribution of systemic lupus erythematosus, polymyositis/dermatomyositis, and systemic sclerosis in Japan. Mod Rheumatol 23(4):759–764
doi: 10.3109/s10165-012-0733-7
Kohsaka H, Mimori T, Kanda T, Shimizu J, Sunada Y, Fujimoto M, Kawaguchi Y, Jinnin M, Muro Y, Ishihara S, Tomimitsu H, Ohta A, Sumida T (2019) Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Neurol Clin Neurosci 7:3–21
doi: 10.1111/ncn3.12223
Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362(9388):971–982
doi: 10.1016/S0140-6736(03)14368-1
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE, RIM Study Groupet (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314–324
doi: 10.1002/art.37754
Christopher-Stine L, Wan GJ, Kelly W, McGowan M, Bostic R, Reed ML (2020) Patient-reported dermatomyositis and polymyositis flare symptoms are associated with disability, productivity loss, and health care resource use. J Manag Care Spec Ph 20(11):1424–1433
Murthy JMK (2010) Drug treatment of polymyositis and dermatomyositis. Neurol India 58(1):3–5
doi: 10.4103/0028-3886.60386
Hunter K, Lyon MG (2012) Evaluation and management of polymyositis. Indian J Dermatol 57(5):371–374
doi: 10.4103/0019-5154.100479
Wang DX, Shu XM, Tian XL, Chen F, Zu N, Ma L, Wang GC (2012) Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review. Clin Rheumatol 31(5):801–806
doi: 10.1007/s10067-012-1940-5
Kohsaka H, Mimori T, Kanda T, Shimizu J, Sunada Y, Fujimoto M, Kawaguchi Y, Jinnin M, Muro Y, Ishihara S, Tomimitsu H, Ohta A, Sumida T (2018) Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. J Dermatol 46(1):e1–e18. https://doi.org/10.1111/1346-8138.14604
doi: 10.1111/1346-8138.14604
pubmed: 30562845
Khosla S, White R, Medina J, Ouwens M, Emmas C, Koder T, Male G, Leonard S (2018) Real world evidence (RWE) – a disruptive innovation or the quiet evolution of medical evidence generation? F1000Res 7:111. https://doi.org/10.12688/f1000research.13585.1
doi: 10.12688/f1000research.13585.1
pubmed: 30026923
pmcid: 6039945
Tomimitsu H, Ohta A, Nagai M, Nishina M, Ishihara S, Kohsaka H (2016) Epidemiologic analysis of the clinical features of Japanese patients with polymyositis and dermatomyositis. Mod Rheumatol 26(3):398–402
doi: 10.3109/14397595.2015.1091137
Big Data (Medical Field) (2021) Japan Medical Data Center. https://www.jmdc.co.jp/en/bigdata . Accessed 2 July 2021
Epstein M (2005) Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 14(8):589–595
doi: 10.1002/pds.1082
World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191–2194
doi: 10.1001/jama.2013.281053
Wang SV, SchnUeeweiss S, Berger ML, Brown J, Vries F, Douglas I, Gagne JJ, Gini R, Klungel O, Mullins CD, Nguyen MD, Rassen JA, Smeeth L, Sturkenboom M, on behalf of the joint ISPE‐ISPOR Special Task Force on Real World Evidence in Health Care Decision Making (2017) Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies. Value Health 20(8):1009–1022
doi: 10.1016/j.jval.2017.08.3018
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43(11):1130–1139
doi: 10.1097/01.mlr.0000182534.19832.83
Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11(1):44–47
doi: 10.1111/j.1524-4733.2007.00213.x
Chen I-J, Tsai W-P, Wu Y-JJ, Luo S-F, Ho H-H, Liou L-B, Chen J-Y, Kuo C-F, Chang H-C, Yang C-H, Yu K-H (2010) Infections in polymyositis and dermatomyositis: analysis of 192 cases. Rheumatol (Oxford) 49(12):2429–2437
doi: 10.1093/rheumatology/keq279
Rare Disease Database (2018) Dermatomyositis. https://rarediseases.org/rare-diseases/dermatomyositis/#:~:text=Polymyositis%20occurs%20most%20often%20in,over%20days%2C%20weeks%20or%20months . Accessed 2 Jun 2021
Syue SH, Chang YH, Shih PJ, Lin CL, Yeh JJ, Kao CH (2020) Polymyositis/dermatomyositis is a potential risk factor for acute respiratory failure: a pulmonary heart disease. Ann Transl Med 8(5):202. https://doi.org/10.21037/atm.2020.01.56
doi: 10.21037/atm.2020.01.56
pubmed: 32309349
pmcid: 7154474
Rai SK, Choi HK, Sayre EC, Avina-Zubieta JA (2016) Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study. Rheumatol (Oxford) 55(3):461–469
Intractable Disease Measures (2009) Outline of intractable disease measures. https://www.mhlw.go.jp/english/wp/wp-hw5/dl/23010223e.pdf . Accessed 2 Jun 2021
Zhang L, Wang GC, Ma L, Zu N (2012) Cardiac involvement in adult polymyositis or dermatomyositis: a systematic review. Clin Cardiol 35(11):686–691
pubmed: 22847365
Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y, Inui N, Yokomura K, Koshimizu N, Toyoshima M, Shirai T, Yasuda K, Hayakawa H, Suda T (2014) Prognostic factors for myositis-associated interstitial lung disease. PLoS One 9(6):e98824
doi: 10.1371/journal.pone.0098824
Clarson LE, Bajpai R, Whittle R, Belcher J, Sultan AA, Kwok CS, Welsh V, Mamas M, Mallen CD (2020) Interstitial lung disease is a risk factor for ischaemic heart disease and myocardial infarction. Heart 106(12):916–922
doi: 10.1136/heartjnl-2019-315511
Lu X, Yang H, Shu X, Chen F, Zhang Y, Zhang S, Peng Q, Tian X, Wang G (2014) Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS One 9(4):e94128
doi: 10.1371/journal.pone.0094128
Dourmishev LA (2017) Inflammatory myopathies with cutaneous involvement: from diagnosis to therapy. Folia Med (Plovdiv) 59(1):7–13
doi: 10.1515/folmed-2017-0003
Tansley S, Shaddick G, Christopher-Stine L, Sharp C, Dourmishev L, Maurer B, Chinoy H, McHugh N (2016) Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferences. Clin Exp Rheumatol 34(5):880–884
pubmed: 27243269
Qushmaq KA, Chalmers A, Esdaile JM (2000) Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol 27:2855–2859
pubmed: 11128676
Rice JB, White A, Lopez A, Galebach P, Schepman P, Popelar B, Philbin M (2016) Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population. J Med Econ 19(7):649–654
doi: 10.3111/13696998.2016.1151433
Donohoe MT, Kravitz RL, Wheeler DB, Chandra R, Chen A, Humphries N (1999) Reasons for outpatient referrals from generalists to specialists. J Gen Intern Med 14:281–286
doi: 10.1046/j.1525-1497.1999.00324.x
Ungprasert P, Wannarong T, Cheungpasitporn W, Wijarnpreecha K, Thongprayoon C, Kroner PT (2020) Inpatient burden and resource utilization of polymyositis and dermatomyositis: A 10-year Study of National Inpatient Sample. Joint Bone Spine 87(4):327–330
doi: 10.1016/j.jbspin.2020.03.002
Misra DP, Agarwal V (2019) Real-world evidence in rheumatic diseases: relevance and lessons learnt. Rheumatol Int 39(3):403–416
doi: 10.1007/s00296-019-04248-1
Rothwell PM (2005) External validity of randomised controlled trials: “To whom do the results of this trial apply?” Lance 365(9453):82–93
doi: 10.1016/S0140-6736(04)17670-8
Fortin M, Dionne J, Pinho G, Gignac J, Almirall J, Lapointe L (2006) Randomized controlled trials: do they have external validity for patients with multiple comorbidities? Ann Fam Med 4(2):104–108
doi: 10.1370/afm.516